Morgan Stanley vs Pfizer Inc — how do they compare? Morgan Stanley trades at $215.31 (market cap $338.50B), while Pfizer Inc trades at $26.59 (market cap $154.18B). The key difference: Morgan Stanley is far larger — about 2.2× Pfizer Inc's market cap, and Pfizer Inc pays the higher dividend (6.36%). Which is the better fit depends on your goals.
| MS | PFE | |
|---|---|---|
Market Cap | $338.50B | $154.18B |
Sector | Financials | Health |
52-Week High | $228.42 | $28.56 |
52-Week Low | $143.88 | $23.60 |
Dividend Yield | 2.14% | 6.36% |
Volume | — | 29,869,932 |
Enterprise Value | — | $205.67B |
Signals from Pluang's Aura AI — not financial advice
Morgan Stanley (MS) trades at $216.26, up 1.18% with a bullish technical outlook and strong earnings beats in recent quarters. Revenue grew to $66.0B in 2025, with net income margin expanding to 25.56%. The stock is supported by analyst consensus price target of $239.58 and recent news of leading Anthropic's IPO, indicating robust business momentum.
Outlook remains positive given earnings growth and institutional support, but risks include volatile cash flows and high debt levels. The stock offers upside to consensus targets, though investors should monitor interest expense impacts and market volatility.
Pfizer (PFE) trades at $26.74, up 2.06% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. Recent quarters show consistent earnings beats, though revenue has moderated from pandemic peaks. The company maintains a strong cash position of $20.48 billion (2024) and a dividend yield supported by a $0.43 per share payout. Key developments include a focus on obesity and oncology pipelines, with several catalysts expected in 2026.
The outlook balances a stable dividend and pipeline potential against post-COVID revenue normalization and patent cliff risks. Near-term upside exists if pipeline catalysts materialize, but investors face headwinds from competitive pressures and projected net income margin compression to 6.8% in 2026. The stock's valuation at a P/E of 35.21 appears elevated relative to earnings growth, warranting caution despite technical strength.
Trailing returns across standard periods
Latest headlines on both assets
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →